Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc.’s Chief Commercial Officer Brian T. Powl sold 448 shares of common stock at $7.27 per share on November 19, 2026. His reported direct holdings after the sale were 112,817 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on May 22, 2026.
Kura Oncology, Inc. officer Brian Powl gave notice of a proposed sale of 448 common shares, with an aggregate market value of $3,288.32 and an approximate sale date of November 19, 2026. The form names Morgan Stanley Smith Barney LLC as broker and NASDAQ as the exchange.
The shares were acquired for cash through the Employee Stock Purchase Plan on November 17, 2026. The notice lists May 22, 2026 as the Rule 10b5-1 plan adoption or instruction date. The prior-three-month table includes a 15,254-share sale for gross proceeds of $113,639.25 on November 17, 2026 and a 15,430-share sale for gross proceeds of $165,852.44 on September 29, 2026; both entries are labeled 10b5-1 sales.
Kura Oncology, Inc. reported a Rule 506(b) exempt equity offering, with $5,000,000 sold and $20,000,000 remaining to be sold.
At Kura Oncology, Inc. (KURA), SVP, Finance & Accounting Thomas James Doyle sold 4,697 common shares at $7.44 per share on November 16, 2026. The sale was a sell-to-cover for taxes associated with vesting one-sixth of the underlying shares of performance-based restricted stock units. His reported direct holdings were 138,081 shares, including 350 acquired November 17 under the Employee Stock Purchase Plan; he also reported 500 indirectly held shares in his spouse’s 401(k). No Rule 10b5-1 plan is reported.
Kura Oncology, Inc. Chief Medical Officer Mollie Leoni reported two direct common-stock sales: 19,009 shares on November 16, 2026, at $7.44 per share, and 22,241 shares on November 17, 2026, at a weighted average of $7.45 per share. The November 17 trades ranged from $7.24 to $7.74 per share and were reported as made under a Rule 10b5-1 plan adopted March 19, 2026. The November 16 sale was a sell-to-cover for taxes associated with vesting of performance-based restricted stock units.
Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported direct sales of 24,450 common shares on November 16 and 17, 2026. The November 16 sale covered 9,196 shares at $7.44 per share to cover taxes associated with vesting of an RSU received on November 13, 2025. On November 17, Powl sold 15,254 shares at a weighted average $7.45 per share under a Rule 10b5-1 trading plan adopted May 22, 2026; executions ranged from $7.24 to $7.74. He also acquired 896 shares through the Employee Stock Purchase Plan on November 17.
Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 8,601 shares of common stock at $7.44 per share on November 16, 2026, under a Rule 10b5-1 trading plan. She held 178,401 shares directly after the sale. The sale covered taxes associated with vesting one-sixth of the underlying shares of performance-based restricted stock units after the one-year anniversary of a specified development milestone was determined to have been met on November 13, 2026.
Kura Oncology, Inc. (KURA) Chief Operating Officer Kathleen Ford reported two direct common-stock sales. She sold 7,042 shares at $7.44 per share on November 16, 2026 in a sell-to-cover for taxes tied to vesting one-sixth of performance-based restricted stock units. On November 17, she sold 3,668 shares at a weighted average $7.46 per share; the reported trades ranged from $7.27 to $7.66. Both sales were under a Rule 10b5-1 trading plan, and the November 17 sale’s footnote says the plan was adopted May 29, 2026.
Kura Oncology, Inc. (KURA) reports that Brian Powl, an officer, filed a notice for the proposed sale of 15,254 common shares on approximately November 17, 2026, with an aggregate market value of $108,150.86. The shares were acquired from the issuer as restricted stock units on November 13, 2026. The notice lists May 22, 2026 as the plan adoption or instruction date for reliance on Rule 10b5-1.
Kura Oncology, Inc. officer Mollie Leoni gave notice of a proposed sale of 22,241 common shares, with an aggregate market value of $157,688.69 and an approximate sale date of November 17, 2026. She acquired the shares from the issuer as performance stock units on November 13, 2026. The stated Rule 10b5-1 plan adoption or instruction date for the proposed sale is March 19, 2026. Leoni’s prior-three-month sales included 19,009 shares for gross proceeds of $141,485.36 on November 16; 28,802 shares for $309,566.78 on September 29, identified as a 10b5-1 sale; and 12,448 shares for $130,670.01 on September 28.